FibroGen, Inc

Listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to David DeLucia, VP of Investor Relations. Please go ahead.

Good afternoon, everyone.

Thank you for joining today to discuss our second quarter of 2024 financial and business results. I'm David DeLaGia, Vice President of Corporate FP&A and Investor Relations at FiberGem. Joining me on today's call are Thayne Wettick, our Chief Executive Officer, Dr. Daya Adib, our Chief Medical Officer, Juan Graham, our Chief Financial Officer, Chris Chung, our Senior Vice President of China Operations, and Dr. John Hunter, our Chief Scientific Officer. Following our prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward looking statements about FibroGen. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, our regulatory strategies and potential regulatory results, our research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events that differ materially from those projected in that statement. A more complete description of these and other material risks can be found in FibreGen's filings with the SEC, including our most recent Form 10-K and Form 10-Q. FibreGen does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information future events, or otherwise. The press release reporting our financial results and business update and a webcast of today's conference call can be found on the investor section of FibreGen's website at www.fibregen.com. With that, I'd like to turn the call over to our CEO, Dane Wedding.